AB SCIENCE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.1 EUR | -4.98% |
|
+5.53% | -40.93% |
| May. 13 | AB Science: European patent granted for masitinib | CF |
| May. 03 | AB Science: upbeat after legal success | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 970K 1.05M | Sales 2024 * | 990K 1.08M | Capitalization | 107M 117M |
|---|---|---|---|---|---|
| Net income 2023 | -10M -10.87M | Net income 2024 * | -18M -19.56M | EV / Sales 2023 | 187 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 108 x |
| P/E ratio 2023 |
-17.8
x | P/E ratio 2024 * |
-5.83
x | Employees | 89 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on AB Science
More press releases
More news
| 1 day | -4.98% | ||
| 1 week | +5.53% | ||
| Current month | +9.49% | ||
| 1 month | +4.22% | ||
| 3 months | -41.42% | ||
| 6 months | -27.34% | ||
| Current year | -40.93% |
1 week
1.99
2.30
1 month
1.862.30
Current year
1.554.47
1 year
1.554.97
3 years
1.5516.68
5 years
1.5521.75
10 years
1.5521.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
| Chief Tech/Sci/R&D Officer | - | 18-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
| Director/Board Member | 62 | 21-06-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 2.1 | -4.98% | 188,925 |
| 24-05-16 | 2.21 | -3.07% | 250,796 |
| 24-05-15 | 2.28 | +8.57% | 299,276 |
| 24-05-14 | 2.1 | +3.45% | 159,668 |
| 24-05-13 | 2.03 | +2.01% | 71,578 |
Real-time Euronext Paris, May 17, 2024 at 11:35 am EDT
More quotes
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-09-29
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.1
EUR
Average target price
6.895
EUR
Spread / Average Target
+228.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.93% | 117M | |
| +10.23% | 8.96B | |
| -10.76% | 5.19B | |
| +51.58% | 4.77B | |
| +12.50% | 4.26B | |
| -20.70% | 2.37B | |
| +12.83% | 2.3B | |
| +19.51% | 2.17B | |
| -29.65% | 2.21B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- AB Stock
